HCPCS Level IIdrugActive
J2327
Inj risankizumab-rzaa 1 mg
BETOS: O1E
Effective: 2023-01-01
Referenced in 1 policies
Description
Injection, risankizumab-rzaa, intravenous, 1 mg
Medicare Part B Drug Pricing
Average Sales Price (ASP) data for Q1 2026
Drug Name
Skyrizi
Manufacturer
AbbVie Inc.
HCPCS Dosage
1 MG
Billing Units
600.0000
1
NDC Products
asp
Pricing Source
Medicare Part B drugs are reimbursed at ASP + 6%. Pricing updates quarterly based on manufacturer-reported data.